Sponsor or institution
Clinical trials and research at Cullinan Therapeutics Inc.
As of November 12, 2026, Find a Trial lists 4 clinical trials run by Cullinan Therapeutics Inc. that are recruiting, at sites in 10 countries (most in Germany (3), United States (3), France (2)). By phase: Phase 1 (3), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 10Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| CLN-978 injections for people with moderate to severe Sjögren's disease | Phase 1 | Orlando, Florida and 13 other locations | Recruiting | Jun 27, 2025 |
| Subcutaneous CLN-978 for treatment‑refractory rheumatoid arthritis | Phase 1 | Erlangen and 3 other locations | Recruiting | May 29, 2025 |
| Using CLN-978 to treat patients with systemic lupus erythematosus | Phase 1 | Avondale, Arizona and 23 other locations | Recruiting | Sep 25, 2024 |
| CLN-049 treatment for patients with relapsed or refractory AML or MDS | Phase 1/2 | Birmingham, Alabama and 16 other locations | Recruiting | Dec 3, 2021 |
All recruiting trials (4)
-
CLN-978 injections for people with moderate to severe Sjögren's disease
This trial will try subcutaneous injections of CLN-978, a CD19-directed T cell engager, in adults with active moderate-to-severe Sjögren's disease to see if it reduces disease activity.
-
Subcutaneous CLN-978 for treatment‑refractory rheumatoid arthritis
This Phase I trial tests a subcutaneously given drug called CLN-978 that redirects T cells to CD19 to try to help people with treatment‑refractory, B‑cell–driven rheumatoid arthritis.
-
Using CLN-978 to treat patients with systemic lupus erythematosus
This study is testing a new treatment called CLN-978 to see if it can help people with moderate to severe lupus who haven't responded well to other treatments.
-
CLN-049 treatment for patients with relapsed or refractory AML or MDS
This study is testing a new treatment called CLN-049 to see if it can help patients with relapsed or hard-to-treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).
Quick answers
How many clinical trials run by Cullinan Therapeutics Inc. are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 10 countries. The most sites are in Germany (3 trials), United States (3 trials), France (2 trials), Italy (2 trials), Australia (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 3, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.